A Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms With AZD8529 in Patients With Schizophrenia.

Trial Profile

A Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms With AZD8529 in Patients With Schizophrenia.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs AZD 8529 (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 31 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 31 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top